Compare DKS & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DKS | ILMN |
|---|---|---|
| Founded | 1948 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.8B | 20.5B |
| IPO Year | N/A | 2000 |
| Metric | DKS | ILMN |
|---|---|---|
| Price | $216.48 | $146.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 16 |
| Target Price | ★ $243.16 | $121.00 |
| AVG Volume (30 Days) | 1.4M | ★ 1.7M |
| Earning Date | 11-25-2025 | 02-05-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 12.28 | 4.46 |
| Revenue | ★ $14,882,715,000.00 | $4,288,000,000.00 |
| Revenue This Year | $31.15 | N/A |
| Revenue Next Year | $26.22 | $2.24 |
| P/E Ratio | ★ $17.56 | $32.63 |
| Revenue Growth | ★ 10.86 | N/A |
| 52 Week Low | $166.37 | $68.70 |
| 52 Week High | $254.60 | $153.06 |
| Indicator | DKS | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 64.00 |
| Support Level | $209.76 | $139.79 |
| Resistance Level | $222.00 | $151.34 |
| Average True Range (ATR) | 7.53 | 4.32 |
| MACD | 1.55 | 0.47 |
| Stochastic Oscillator | 77.61 | 76.48 |
Dick's Sporting Goods is a retailer that offers sports and outdoor apparel, footwear, and equipment online and in physical stores. The company's legacy business includes more than 700 stores under its own name, more than 100 Golf Galaxy golf specialty stores, and about 50 outlet stores. In September 2025, Dick's acquired multinational retailer Foot Locker. With this move, Dick's added more than 2,300 stores under the Foot Locker, Kids Foot Locker, Champs Sports, atmos, and WSS nameplates in North America, the Asia-Pacific, and EMEA—Europe, the Middle East, and Africa. Based in the Pittsburgh area, Dick's was founded in 1948 by the father of current executive chair and controlling shareholder Edward Stack.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.